NCT02086227View on ClinicalTrials.gov

Bioequivalence of Fresenius Kabi USA, LLC Glucagon for SC Injection Compared to Glucagon for Injection (Bedford Laboratories)

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

June 30, 2013

Study Completion Date

June 30, 2013

Conditions
Hypoglycemia
Interventions
DRUG

Glucagon for Injection (Fresenius Kabi USA)

Test product: A 1 mg (1 IU/ml) Glucagon for Injection (Fresenius Kabi USA)

DRUG

Glucagon for Injection (Bedford Laboratories)

Reference product: B 1 mg (1 IU/ml) of GlucaGen® for Injection (Bedford Laboratories)

Trial Locations (1)

77055

West Houston Clinical Research Services, 2026 Wirt Road, Houston

Sponsors
All Listed Sponsors
lead

Fresenius Kabi USA, LLC

INDUSTRY

NCT02086227 - Bioequivalence of Fresenius Kabi USA, LLC Glucagon for SC Injection Compared to Glucagon for Injection (Bedford Laboratories) | Biotech Hunter | Biotech Hunter